Edwards Lifesciences Co. (NYSE:EW) Stock Holdings Lifted by Royal London Asset Management Ltd.

Royal London Asset Management Ltd. grew its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 2.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 251,205 shares of the medical research company's stock after acquiring an additional 5,027 shares during the period. Royal London Asset Management Ltd.'s holdings in Edwards Lifesciences were worth $18,597,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Abacus Planning Group Inc. grew its stake in Edwards Lifesciences by 0.3% during the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company's stock valued at $2,977,000 after purchasing an additional 140 shares in the last quarter. Bowman & Co S.C. boosted its stake in shares of Edwards Lifesciences by 1.2% during the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company's stock valued at $924,000 after buying an additional 148 shares during the last quarter. Moors & Cabot Inc. grew its position in shares of Edwards Lifesciences by 0.3% during the fourth quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company's stock worth $4,041,000 after buying an additional 152 shares in the last quarter. Pegasus Asset Management Inc. increased its stake in shares of Edwards Lifesciences by 0.4% in the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company's stock worth $3,156,000 after buying an additional 159 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC raised its holdings in Edwards Lifesciences by 1.9% in the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company's stock valued at $634,000 after acquiring an additional 162 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now owns 60,372 shares in the company, valued at $4,613,628.24. This represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 51,303 shares of company stock valued at $3,715,776. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Price Performance

NYSE:EW traded down $0.12 during trading hours on Wednesday, reaching $71.12. 3,487,871 shares of the company's stock were exchanged, compared to its average volume of 4,572,641. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $41.81 billion, a P/E ratio of 10.20, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The business's 50-day simple moving average is $71.43 and its two-hundred day simple moving average is $70.45.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the subject of a number of research reports. Bank of America upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. Canaccord Genuity Group lifted their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research note on Thursday, February 13th. Stifel Nicolaus upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their price objective for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Barclays raised their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.